Current stock page

Catalysts

NRIX Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

NRIXNurix Therapeutics, Inc.

Healthcare / Biotechnology

Leader

Strong Relative Position

BullishEdge 8/10
$15.48−$0.12 (−0.77%)

Latest quote

  • Momentum
    50
  • Value
    94
  • Quality
    78
  • Risk resilience
    40
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Jan 27, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 65/100

Momentum 50/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 15, 2026 · Sentiment -5.35%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 50/100AIQ Edge 8/10 Strong Relative Position
Beat rate
50%
4 of 8 reported periods
Average surprise
+109.1%
Across covered historical reports
Latest result
+887.1%
Oct 12, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Oct 12, 2026—-$0.60$4.73+887.1%$24.35M$673.06M
Jul 9, 2026—-$0.72-$0.81-12.1%$15.29M$9.04M
Apr 8, 2026—-$0.76-$0.79-3.9%$14.25M$6.25M
Jan 28, 2026—-$0.84-$0.82+2.4%$13.4M$13.58M
Oct 9, 2025—-$0.84-$1.03-22.6%$12.26M$7.89M
Jul 9, 2025—-$0.71-$0.52+26.8%$17.51M$44.06M
Apr 8, 2025—-$0.72-$0.67+6.9%$15.82M$18.45M
Jan 28, 2025—-$0.67-$0.75-11.9%$14.78M$13.28M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
13
Buy
1
Hold
12-month analyst target
$33.63
+117.22% versus current price
Based on 14 analyst observations. Targets are estimates, not predictions.
Low target
$20.00
+29.20% vs latest price
Average target
$33.63
+117.22% vs latest price
High target
$41.00
+164.86% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateJan 27, 2027

Next known earnings or reporting date.

EPS estimate-$0.46

Current analyst expectation for the upcoming report.

Revenue estimate$287.86M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score50

Where event reaction would show up first.

AIQ score65/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
14
Average target
$33.63
Target upside
117.22%
Target range
$20.00 - $41.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
2
Neutral
2
Negative
1
rttnews.com · Nov 4, 2026

Morning Market Movers: CRIS, DKI, DOX, NRIX See Big Swings

As markets react to the outcome of the U.S. midterm elections, premarket trading is seeing notable activity in several stocks, particularly CRIS, DKI, DOX and NRIX.

gurufocus.com · Oct 14, 2026

NRIX SWOT Analysis: Financial Challenges and Promising Pipeline Revealed in 10-Q Filing

Strengths include a robust pipeline of drug candidates and strategic collaborations with major pharmaceutical companies.Weaknesses highlight significant financi

gurufocus.com · Oct 13, 2026

NRIX Maintained by Oppenheimer -- Price Target Raised to $32

Nurix Therapeutics (NRIX) Analyst Rating Update On October 3, 2023, Oppenheimer has maintained its "Outperform" rating for Nurix Therapeutics (NRIX) while ra

zacks.com · Oct 12, 2026

Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates

Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of +944.64% and +383.11%, respectively, for the quarter ended August 2026. Do the numbers hold clues to what lies ahead for the stock?

seekingalpha.com · Oct 12, 2026

Nurix Therapeutics GAAP EPS of $4.73 beats by $1.64, revenue of $673.1M beats by $193.58M (NASDAQ:NRIX)

Nurix Therapeutics press release (NRIX): Q3 GAAP EPS of $4.73 beats by $1.64. Revenue of $673.1M (+8420.3% Y/Y) beats by $193.58M. Cash, cash equivalents and ma

Open full news and sentiment

NRIX Catalysts FAQ

What are the next catalysts for NRIX stock?

NRIX's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move NRIX stock?

Upcoming events that could move NRIX include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could NRIX's next earnings report affect the stock?

NRIX's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive NRIX stock higher?

NRIX could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt NRIX stock?

NRIX could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.